{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T17:04:30Z","timestamp":1758474270951,"version":"3.32.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"DOI":"10.1007\/s10637-024-01503-6","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T18:42:21Z","timestamp":1736448141000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Investigation of the association between therapeutic effectiveness of anamorelin and Glasgow prognostic score in patients with cancer cachexia: a competing risk analysis"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2093-3695","authenticated-orcid":false,"given":"Kazuhiro","family":"Shimomura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takatsugu","family":"Ogata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akimitsu","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukiya","family":"Narita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroya","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenta","family":"Murotani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Tajika","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Hara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Muro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosaku","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,9]]},"reference":[{"key":"1503_CR1","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/nrc3829","volume":"14","author":"JM Argil\u00e9s","year":"2014","unstructured":"Argil\u00e9s JM, Busquets S, Stemmler B, L\u00f3pez-Soriano FJ (2014) Cancer cachexia: understanding the molecular basis. Nat Rev Cancer 14:754\u2013762. https:\/\/doi.org\/10.1038\/nrc3829","journal-title":"Nat Rev Cancer"},{"key":"1503_CR2","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon K, Strasser F, Anker SD et al (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12:489\u2013495. https:\/\/doi.org\/10.1016\/S1470-2045(10)70218-7","journal-title":"Lancet Oncol"},{"key":"1503_CR3","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s13539-014-0164-8","volume":"5","author":"S von Haehling","year":"2014","unstructured":"von Haehling S, Anker SD (2014) Prevalence, incidence and clinical impact of cachexia: facts and numbers\u2014update 2014. J Cachexia Sarcopenia Muscle 5:261\u2013263. https:\/\/doi.org\/10.1007\/s13539-014-0164-8","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"1503_CR4","first-page":"1107","volume":"7","author":"A Schcolnik-Cabrera","year":"2017","unstructured":"Schcolnik-Cabrera A, Ch\u00e1vez-Blanco A, Dom\u00ednguez-G\u00f3mez G, Due\u00f1as-Gonz\u00e1lez A (2017) Understanding tumor anabolism and patient catabolism in cancer-associated cachexia. Am J Cancer Res 7:1107\u20131135","journal-title":"Am J Cancer Res"},{"key":"1503_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.clnu.2016.07.015","volume":"36","author":"J Arends","year":"2017","unstructured":"Arends J, Bachmann P, Baracos V et al (2017) ESPEN guidelines on nutrition in cancer patients. Clin Nutr 36:11\u201348. https:\/\/doi.org\/10.1016\/j.clnu.2016.07.015","journal-title":"Clin Nutr"},{"key":"1503_CR6","doi-asserted-by":"publisher","first-page":"789","DOI":"10.2217\/fon.14.14","volume":"10","author":"DC Currow","year":"2014","unstructured":"Currow DC, Abernethy AP (2014) Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome. Futur Oncol 10:789\u2013802. https:\/\/doi.org\/10.2217\/fon.14.14","journal-title":"Futur Oncol"},{"key":"1503_CR7","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.2147\/DDDT.S110131","volume":"11","author":"SA Graf","year":"2017","unstructured":"Graf SA, Garcia JM (2017) Anamorelin hydrochloride in the treatment of cancer anorexia\u2013cachexia syndrome: design, development, and potential place in therapy. Drug Des Devel Ther 11:2325\u20132331. https:\/\/doi.org\/10.2147\/DDDT.S110131","journal-title":"Drug Des Devel Ther"},{"key":"1503_CR8","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1470-2045(15)00558-6","volume":"17","author":"JS Temel","year":"2016","unstructured":"Temel JS, Abernethy AP, Currow DC et al (2016) Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol 17:519\u2013531. https:\/\/doi.org\/10.1016\/S1470-2045(15)00558-6","journal-title":"Lancet Oncol"},{"key":"1503_CR9","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/cncr.31128","volume":"124","author":"N Katakami","year":"2018","unstructured":"Katakami N, Uchino J, Yokoyama T et al (2018) Anamorelin (ONO-7643) for the treatment of patients with non\u2013small cell lung cancer and cachexia: results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04). Cancer 124:606\u2013616. https:\/\/doi.org\/10.1002\/cncr.31128","journal-title":"Cancer"},{"key":"1503_CR10","doi-asserted-by":"publisher","first-page":"4294","DOI":"10.1002\/cncr.32406","volume":"125","author":"S Hamauchi","year":"2019","unstructured":"Hamauchi S, Furuse J, Takano T et al (2019) A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia. Cancer 125:4294\u20134302. https:\/\/doi.org\/10.1002\/cncr.32406","journal-title":"Cancer"},{"key":"1503_CR11","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1007\/s00520-016-3144-z","volume":"24","author":"K Takayama","year":"2016","unstructured":"Takayama K, Katakami N, Yokoyama T et al (2016) Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial. Support Care Cancer 24:3495\u20133505. https:\/\/doi.org\/10.1007\/s00520-016-3144-z","journal-title":"Support Care Cancer"},{"key":"1503_CR12","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.nut.2008.06.016","volume":"24","author":"S Shioda","year":"2008","unstructured":"Shioda S, Takenoya F, Yagi M et al (2008) Neural networks of several novel neuropeptides involved in feeding regulation. Nutrition 24:848\u2013853. https:\/\/doi.org\/10.1016\/j.nut.2008.06.016","journal-title":"Nutrition"},{"key":"1503_CR13","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1097\/MCO.0000000000000075","volume":"17","author":"A Molfino","year":"2014","unstructured":"Molfino A, Formiconi A, Rossi Fanelli F, Muscaritoli M (2014) Ghrelin: from discovery to cancer cachexia therapy. Curr Opin Clin Nutr Metab Care 17:471\u2013476. https:\/\/doi.org\/10.1097\/MCO.0000000000000075","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"1503_CR14","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1016\/j.biocel.2013.07.016","volume":"45","author":"M Amitani","year":"2013","unstructured":"Amitani M, Asakawa A, Amitani H, Inui A (2013) Control of food intake and muscle wasting in cachexia. Int J Biochem Cell Biol 45:2179\u20132185. https:\/\/doi.org\/10.1016\/j.biocel.2013.07.016","journal-title":"Int J Biochem Cell Biol"},{"key":"1503_CR15","doi-asserted-by":"publisher","first-page":"945","DOI":"10.7314\/APJCP.2014.15.2.945","volume":"15","author":"QQ Li","year":"2014","unstructured":"Li QQ, Lu ZH, Yang L et al (2014) Neutrophil count and the inflammation-based Glasgow prognostic score predict survival in patients with advanced gastric cancer receiving first-line chemotherapy. Asian Pacific J Cancer Prev 15:945\u2013950. https:\/\/doi.org\/10.7314\/APJCP.2014.15.2.945","journal-title":"Asian Pacific J Cancer Prev"},{"key":"1503_CR16","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1159\/000094562","volume":"6","author":"P Glen","year":"2006","unstructured":"Glen P, Jamieson NB, McMillan DC et al (2006) Evaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancer. Pancreatology 6:450\u2013453. https:\/\/doi.org\/10.1159\/000094562","journal-title":"Pancreatology"},{"key":"1503_CR17","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1207\/s15327914nc5501_10","volume":"55","author":"JA Read","year":"2006","unstructured":"Read JA, Choy STB, Beale PJ, Clarke SJ (2006) Evaluation of nutritional and inflammatory status of advanced colorectal cancer patients and its correlation with survival. Nutr Cancer 55:78\u201385. https:\/\/doi.org\/10.1207\/s15327914nc5501_10","journal-title":"Nutr Cancer"},{"key":"1503_CR18","doi-asserted-by":"publisher","first-page":"0","DOI":"10.1177\/11795549221086578","volume":"16","author":"K Stokke","year":"2022","unstructured":"Stokke K, Sandvei MS, Gr\u00f8nberg BH et al (2022) Prognostic value of post first-line chemotherapy Glasgow prognostic score in advanced non-small cell lung cancer. Clin Med Insights Oncol 16:0\u20137. https:\/\/doi.org\/10.1177\/11795549221086578","journal-title":"Clin Med Insights Oncol"},{"key":"1503_CR19","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/sj.bjc.6602922","volume":"94","author":"AM Al Murri","year":"2006","unstructured":"Al Murri AM, Bartlett JMS, Canney PA et al (2006) Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer. Br J Cancer 94:227\u2013230. https:\/\/doi.org\/10.1038\/sj.bjc.6602922","journal-title":"Br J Cancer"},{"key":"1503_CR20","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1002\/jcsm.12912","volume":"13","author":"DR Paval","year":"2022","unstructured":"Paval DR, Patton R, McDonald J et al (2022) A systematic review examining the relationship between cytokines and cachexia in incurable cancer. J Cachexia Sarcopenia Muscle 13:824\u2013838. https:\/\/doi.org\/10.1002\/jcsm.12912","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"1503_CR21","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.ctrv.2012.08.003","volume":"39","author":"DC McMillan","year":"2013","unstructured":"McMillan DC (2013) The systemic inflammation-based Glasgow prognostic score: a decade of experience in patients with cancer. Cancer Treat Rev 39:534\u2013540. https:\/\/doi.org\/10.1016\/j.ctrv.2012.08.003","journal-title":"Cancer Treat Rev"},{"key":"1503_CR22","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1515\/CCLM.2008.089","volume":"46","author":"M Krzystek-Korpacka","year":"2008","unstructured":"Krzystek-Korpacka M, Matusiewicz M, Diakowska D et al (2008) Acute-phase response proteins are related to cachexia and accelerated angiogenesis in gastroesophageal cancers. Clin Chem Lab Med 46:359\u2013364. https:\/\/doi.org\/10.1515\/CCLM.2008.089","journal-title":"Clin Chem Lab Med"},{"key":"1503_CR23","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.ctrv.2013.11.007","volume":"40","author":"E Douglas","year":"2014","unstructured":"Douglas E, McMillan DC (2014) Towards a simple objective framework for the investigation and treatment of cancer cachexia: the Glasgow prognostic score. Cancer Treat Rev 40:685\u2013691. https:\/\/doi.org\/10.1016\/j.ctrv.2013.11.007","journal-title":"Cancer Treat Rev"},{"key":"1503_CR24","doi-asserted-by":"publisher","first-page":"17","DOI":"10.4251\/wjgo.v7.i4.17","volume":"7","author":"T Aoyagi","year":"2015","unstructured":"Aoyagi T, Terracina KP, Raza A et al (2015) Cancer cachexia, mechanism and treatment. World J Gastrointest Oncol 7:17\u201329. https:\/\/doi.org\/10.4251\/wjgo.v7.i4.17","journal-title":"World J Gastrointest Oncol"},{"key":"1503_CR25","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/sj.bjc.6601242","volume":"89","author":"LM Forrest","year":"2003","unstructured":"Forrest LM, McMillan DC, McArdle CS et al (2003) Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer 89:1028\u20131030. https:\/\/doi.org\/10.1038\/sj.bjc.6601242","journal-title":"Br J Cancer"},{"key":"1503_CR26","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0. (2017). Available online: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_40. Accessed 1 Sep 2022"},{"key":"1503_CR27","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1177\/0962280206074463","volume":"16","author":"S van Buuren","year":"2007","unstructured":"van Buuren S (2007) Multiple imputation of discrete and continuous data by fully conditional specification. Stat Methods Med Res 16:219\u2013242. https:\/\/doi.org\/10.1177\/0962280206074463","journal-title":"Stat Methods Med Res"},{"key":"1503_CR28","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jclinepi.2021.01.008","volume":"134","author":"KJ Lee","year":"2021","unstructured":"Lee KJ, Tilling KM, Cornish RP et al (2021) Framework for the treatment and reporting of missing data in observational studies: the treatment and reporting of missing data in observational studies framework. J Clin Epidemiol 134:79\u201388. https:\/\/doi.org\/10.1016\/j.jclinepi.2021.01.008","journal-title":"J Clin Epidemiol"},{"key":"1503_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00520-023-07576-y","volume":"31","author":"N Iwai","year":"2023","unstructured":"Iwai N, Sakai H, Oka K et al (2023) Predictors of response to anamorelin in gastrointestinal cancer patients with cachexia: a retrospective study. Support Care Cancer 31:1\u20138. https:\/\/doi.org\/10.1007\/s00520-023-07576-y","journal-title":"Support Care Cancer"},{"key":"1503_CR30","doi-asserted-by":"publisher","first-page":"100092","DOI":"10.1016\/j.esmoop.2021.100092","volume":"6","author":"J Arends","year":"2021","unstructured":"Arends J, Strasser F, Gonella S et al (2021) Cancer cachexia in adult patients: ESMO clinical practice guidelines. ESMO Open 6:100092. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100092","journal-title":"ESMO Open"},{"key":"1503_CR31","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1200\/JCO.20.00611","volume":"38","author":"EJ Roeland","year":"2020","unstructured":"Roeland EJ, Bohlke K, Baracos VE et al (2020) Management of cancer cachexia: ASCO guideline. J Clin Oncol 38:2438\u20132453. https:\/\/doi.org\/10.1200\/JCO.20.00611","journal-title":"J Clin Oncol"},{"key":"1503_CR32","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1002\/jcsm.13323","volume":"14","author":"H Arai","year":"2023","unstructured":"Arai H, Maeda K, Wakabayashi H et al (2023) Diagnosis and outcomes of cachexia in Asia: working consensus report from the asian working group for cachexia. J Cachexia Sarcopenia Muscle 14:1949\u20131958. https:\/\/doi.org\/10.1002\/jcsm.13323","journal-title":"J Cachexia Sarcopenia Muscle"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-024-01503-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-024-01503-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-024-01503-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T19:05:11Z","timestamp":1736449511000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-024-01503-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,9]]},"references-count":32,"alternative-id":["1503"],"URL":"https:\/\/doi.org\/10.1007\/s10637-024-01503-6","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,9]]},"assertion":[{"value":"11 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in this study involving human participants were in accordance with the provisions of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. This study was approved by the Institutional Review Board of Aichi Cancer Center Hospital (No. 2022\u20130-139).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The ethics committee waived the need for formal consent from the participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Takatsugu Ogata received honoraria from Ono Pharmaceutical Co., Bristol-Myers Squibb, and Taiho Pharmaceutical Co. Yukiya Narita received honoraria and research funds from Ono Pharmaceutical Co., Bristol-Myers Squibb K.K., and Daiichi Sankyo Co., honoraria from Eli Lilly, Yakult Honsha Co., and Taiho Pharmaceutical Co., and research funds from Astrazeneca K.K. Hiroya Taniguchi received honoraria from Ono Pharmaceutical Co. Kenta Murotani received honoraria from Chugai Pharmaceutical Co., Ltd., and Astrazeneca K.K. Yutaka Fujiwara received advisor fees from Daiichi Sankyo Co., honoraria and research funding from AstraZeneca K.K., and research funding from AbbVie G.K., Amgen Inc., AnHeart Therapeutics Inc., Eli Lilly Japan K.K., Incyte, and Merck Sharp & Dohme. Kei Muro received honoraria and research funding from Amgen Inc., Astellas Pharma Inc., Chugai Pharmaceutical Co., MSD K.K., and Ono Pharmaceutical Co., and Taiho Pharmaceutical Co. and honoraria from Daiichi Sankyo Co., Bristol-Myers Squibb K.K., Eli Lilly Japan K.K., Takeda Pharmaceutical Co., and research funding from Novartis Pharma K.K., PRA Health Sciences Inc., PARAXEL International Inc., and Sanofi K.K.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}